Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Utility of Left Ventricular Ejection Fraction Measurements Before the Administration of Doxorubicin-Based Chemotherapy in Patients With Diffuse Large B-Cell Lymphoma.

Enns DL, Mandelson MT, Aboulafia DM.

Mayo Clin Proc Innov Qual Outcomes. 2018 Aug 3;2(3):277-285. doi: 10.1016/j.mayocpiqo.2018.06.004. eCollection 2018 Sep.

2.

Gemcitabine and Taxane Adjuvant Therapy with Chemoradiation in Resected Pancreatic Cancer: A Novel Strategy for Improved Survival?

Kanji ZS, Edwards AM, Mandelson MT, Sahar N, Lin BS, Badiozamani K, Song G, Alseidi A, Biehl TR, Kozarek RA, Helton WS, Picozzi VJ, Rocha FG.

Ann Surg Oncol. 2018 Apr;25(4):1052-1060. doi: 10.1245/s10434-018-6334-8. Epub 2018 Jan 17.

PMID:
29344878
3.

Utility of Bone Marrow Biopsy and Aspirate for Staging of Diffuse Large B Cell Lymphoma in the Era of Positron Emission Tomography With 2-Deoxy-2-[Fluorine-18]fluoro-deoxyglucose Integrated With Computed Tomography.

Vishnu P, Wingerson A, Lee M, Mandelson MT, Aboulafia DM.

Clin Lymphoma Myeloma Leuk. 2017 Oct;17(10):631-636. doi: 10.1016/j.clml.2017.06.010. Epub 2017 Jun 17.

PMID:
28684378
4.

Adenoma Prevalence in Blacks and Whites Having Equal Adherence To Screening Colonoscopy: The National Colonoscopy Study.

Mendelsohn RB, Winawer SJ, Jammula A, Mills G, Jordan P, O'Brien MJ, Close GM, Dorfman M, Church TR, Mandelson MT, Allen J, Feld A, Kauff ND, Morgan GA, Kumar JMR, Serrano V, Bayuga-Miller S, Fischer SE, Kuk D, Zauber AG.

Clin Gastroenterol Hepatol. 2017 Sep;15(9):1469-1470. doi: 10.1016/j.cgh.2017.04.014. Epub 2017 Apr 15. No abstract available.

5.

Five-Year Actual Overall Survival in Resected Pancreatic Cancer: A Contemporary Single-Institution Experience from a Multidisciplinary Perspective.

Picozzi VJ, Oh SY, Edwards A, Mandelson MT, Dorer R, Rocha FG, Alseidi A, Biehl T, Traverso LW, Helton WS, Kozarek RA.

Ann Surg Oncol. 2017 Jun;24(6):1722-1730. doi: 10.1245/s10434-016-5716-z. Epub 2017 Jan 4.

PMID:
28054192
6.

Localized pancreatic cancer with positive peritoneal cytology as a sole manifestation of metastatic disease: a single-institution experience.

Oh SY, Edwards A, Mandelson MT, Hahn H, Alseidi A, Biehl T, Kozarek RA, Rocha FG, Helton S, Picozzi VJ.

Am J Surg. 2017 Jan;213(1):94-99. doi: 10.1016/j.amjsurg.2016.04.008. Epub 2016 Jun 12.

PMID:
27424044
7.

Rare long-term survivors of pancreatic adenocarcinoma without curative resection.

Oh SY, Edwards A, Mandelson MT, Lin B, Dorer R, Helton WS, Kozarek RA, Picozzi VJ.

World J Gastroenterol. 2015 Dec 28;21(48):13574-81. doi: 10.3748/wjg.v21.i48.13574.

8.

An absolute risk model to identify individuals at elevated risk for pancreatic cancer in the general population.

Klein AP, Lindström S, Mendelsohn JB, Steplowski E, Arslan AA, Bueno-de-Mesquita HB, Fuchs CS, Gallinger S, Gross M, Helzlsouer K, Holly EA, Jacobs EJ, Lacroix A, Li D, Mandelson MT, Olson SH, Petersen GM, Risch HA, Stolzenberg-Solomon RZ, Zheng W, Amundadottir L, Albanes D, Allen NE, Bamlet WR, Boutron-Ruault MC, Buring JE, Bracci PM, Canzian F, Clipp S, Cotterchio M, Duell EJ, Elena J, Gaziano JM, Giovannucci EL, Goggins M, Hallmans G, Hassan M, Hutchinson A, Hunter DJ, Kooperberg C, Kurtz RC, Liu S, Overvad K, Palli D, Patel AV, Rabe KG, Shu XO, Slimani N, Tobias GS, Trichopoulos D, Van Den Eeden SK, Vineis P, Virtamo J, Wactawski-Wende J, Wolpin BM, Yu H, Yu K, Zeleniuch-Jacquotte A, Chanock SJ, Hoover RN, Hartge P, Kraft P.

PLoS One. 2013 Sep 13;8(9):e72311. doi: 10.1371/journal.pone.0072311. eCollection 2013.

9.

Family history of diabetes and pancreatic cancer as risk factors for pancreatic cancer: the PACIFIC study.

Austin MA, Kuo E, Van Den Eeden SK, Mandelson MT, Brentnall TA, Kamineni A, Potter JD.

Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1913-7. doi: 10.1158/1055-9965.EPI-13-0518. Epub 2013 Aug 21.

10.

Polymorphisms in genes related to one-carbon metabolism are not related to pancreatic cancer in PanScan and PanC4.

Leenders M, Bhattacharjee S, Vineis P, Stevens V, Bueno-de-Mesquita HB, Shu XO, Amundadottir L, Gross M, Tobias GS, Wactawski-Wende J, Arslan AA, Duell EJ, Fuchs CS, Gallinger S, Hartge P, Hoover RN, Holly EA, Jacobs EJ, Klein AP, Kooperberg C, LaCroix A, Li D, Mandelson MT, Olson SH, Petersen G, Risch HA, Yu K, Wolpin BM, Zheng W, Agalliu I, Albanes D, Boutron-Ruault MC, Bracci PM, Buring JE, Canzian F, Chang K, Chanock SJ, Cotterchio M, Gaziano JM, Giovanucci EL, Goggins M, Hallmans G, Hankinson SE, Hoffman-Bolton JA, Hunter DJ, Hutchinson A, Jacobs KB, Jenab M, Khaw KT, Kraft P, Krogh V, Kurtz RC, McWilliams RR, Mendelsohn JB, Patel AV, Rabe KG, Riboli E, Tjønneland A, Trichopoulos D, Virtamo J, Visvanathan K, Elena JW, Yu H, Zeleniuch-Jacquotte A, Stolzenberg-Solomon RZ.

Cancer Causes Control. 2013 Mar;24(3):595-602. doi: 10.1007/s10552-012-0138-0. Epub 2013 Jan 19.

11.

Detectable clonal mosaicism and its relationship to aging and cancer.

Jacobs KB, Yeager M, Zhou W, Wacholder S, Wang Z, Rodriguez-Santiago B, Hutchinson A, Deng X, Liu C, Horner MJ, Cullen M, Epstein CG, Burdett L, Dean MC, Chatterjee N, Sampson J, Chung CC, Kovaks J, Gapstur SM, Stevens VL, Teras LT, Gaudet MM, Albanes D, Weinstein SJ, Virtamo J, Taylor PR, Freedman ND, Abnet CC, Goldstein AM, Hu N, Yu K, Yuan JM, Liao L, Ding T, Qiao YL, Gao YT, Koh WP, Xiang YB, Tang ZZ, Fan JH, Aldrich MC, Amos C, Blot WJ, Bock CH, Gillanders EM, Harris CC, Haiman CA, Henderson BE, Kolonel LN, Le Marchand L, McNeill LH, Rybicki BA, Schwartz AG, Signorello LB, Spitz MR, Wiencke JK, Wrensch M, Wu X, Zanetti KA, Ziegler RG, Figueroa JD, Garcia-Closas M, Malats N, Marenne G, Prokunina-Olsson L, Baris D, Schwenn M, Johnson A, Landi MT, Goldin L, Consonni D, Bertazzi PA, Rotunno M, Rajaraman P, Andersson U, Beane Freeman LE, Berg CD, Buring JE, Butler MA, Carreon T, Feychting M, Ahlbom A, Gaziano JM, Giles GG, Hallmans G, Hankinson SE, Hartge P, Henriksson R, Inskip PD, Johansen C, Landgren A, McKean-Cowdin R, Michaud DS, Melin BS, Peters U, Ruder AM, Sesso HD, Severi G, Shu XO, Visvanathan K, White E, Wolk A, Zeleniuch-Jacquotte A, Zheng W, Silverman DT, Kogevinas M, Gonzalez JR, Villa O, Li D, Duell EJ, Risch HA, Olson SH, Kooperberg C, Wolpin BM, Jiao L, Hassan M, Wheeler W, Arslan AA, Bueno-de-Mesquita HB, Fuchs CS, Gallinger S, Gross MD, Holly EA, Klein AP, LaCroix A, Mandelson MT, Petersen G, Boutron-Ruault MC, Bracci PM, Canzian F, Chang K, Cotterchio M, Giovannucci EL, Goggins M, Hoffman Bolton JA, Jenab M, Khaw KT, Krogh V, Kurtz RC, McWilliams RR, Mendelsohn JB, Rabe KG, Riboli E, Tjønneland A, Tobias GS, Trichopoulos D, Elena JW, Yu H, Amundadottir L, Stolzenberg-Solomon RZ, Kraft P, Schumacher F, Stram D, Savage SA, Mirabello L, Andrulis IL, Wunder JS, Patiño García A, Sierrasesúmaga L, Barkauskas DA, Gorlick RG, Purdue M, Chow WH, Moore LE, Schwartz KL, Davis FG, Hsing AW, Berndt SI, Black A, Wentzensen N, Brinton LA, Lissowska J, Peplonska B, McGlynn KA, Cook MB, Graubard BI, Kratz CP, Greene MH, Erickson RL, Hunter DJ, Thomas G, Hoover RN, Real FX, Fraumeni JF Jr, Caporaso NE, Tucker M, Rothman N, Pérez-Jurado LA, Chanock SJ.

Nat Genet. 2012 May 6;44(6):651-8. doi: 10.1038/ng.2270.

12.

Pathway analysis of genome-wide association study data highlights pancreatic development genes as susceptibility factors for pancreatic cancer.

Li D, Duell EJ, Yu K, Risch HA, Olson SH, Kooperberg C, Wolpin BM, Jiao L, Dong X, Wheeler B, Arslan AA, Bueno-de-Mesquita HB, Fuchs CS, Gallinger S, Gross M, Hartge P, Hoover RN, Holly EA, Jacobs EJ, Klein AP, LaCroix A, Mandelson MT, Petersen G, Zheng W, Agalliu I, Albanes D, Boutron-Ruault MC, Bracci PM, Buring JE, Canzian F, Chang K, Chanock SJ, Cotterchio M, Gaziano JM, Giovannucci EL, Goggins M, Hallmans G, Hankinson SE, Hoffman Bolton JA, Hunter DJ, Hutchinson A, Jacobs KB, Jenab M, Khaw KT, Kraft P, Krogh V, Kurtz RC, McWilliams RR, Mendelsohn JB, Patel AV, Rabe KG, Riboli E, Shu XO, Tjønneland A, Tobias GS, Trichopoulos D, Virtamo J, Visvanathan K, Watters J, Yu H, Zeleniuch-Jacquotte A, Amundadottir L, Stolzenberg-Solomon RZ.

Carcinogenesis. 2012 Jul;33(7):1384-90. doi: 10.1093/carcin/bgs151. Epub 2012 Apr 20.

13.

Adverse events after screening and follow-up colonoscopy.

Rutter CM, Johnson E, Miglioretti DL, Mandelson MT, Inadomi J, Buist DS.

Cancer Causes Control. 2012 Feb;23(2):289-96. doi: 10.1007/s10552-011-9878-5. Epub 2011 Nov 22.

14.

No evidence for human papillomavirus in the etiology of colorectal polyps.

Burnett-Hartman AN, Newcomb PA, Mandelson MT, Galloway DA, Madeleine MM, Wurscher MA, Carter JJ, Makar KW, Potter JD, Schwartz SM.

Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2288-97. doi: 10.1158/1055-9965.EPI-11-0450. Epub 2011 Aug 4.

15.

Colorectal polyp type and the association with charred meat consumption, smoking, and microsomal epoxide hydrolase polymorphisms.

Burnett-Hartman AN, Newcomb PA, Mandelson MT, Adams SV, Wernli KJ, Shadman M, Wurscher MA, Makar KW.

Nutr Cancer. 2011;63(4):583-92. doi: 10.1080/01635581.2011.553021.

16.

Circulating 25-hydroxyvitamin-D and risk of colorectal adenomas and hyperplastic polyps.

Adams SV, Newcomb PA, Burnett-Hartman AN, White E, Mandelson MT, Potter JD.

Nutr Cancer. 2011;63(3):319-26. doi: 10.1080/01635581.2011.535960.

17.

Body size, IGF and growth hormone polymorphisms, and colorectal adenomas and hyperplastic polyps.

Wernli KJ, Newcomb PA, Wang Y, Makar KW, Shadman M, Chia VM, Burnett-Hartman A, Wurscher MA, Zheng Y, Mandelson MT.

Growth Horm IGF Res. 2010 Aug;20(4):305-9. doi: 10.1016/j.ghir.2010.04.001. Epub 2010 May 26.

18.

Colorectal cancer risk in relation to antidepressant medication use.

Chubak J, Boudreau DM, Rulyak SJ, Mandelson MT.

Int J Cancer. 2011 Jan 1;128(1):227-32. doi: 10.1002/ijc.25322.

19.

Association of diabetes susceptibility gene calpain-10 with pancreatic cancer among smokers.

Fong PY, Fesinmeyer MD, White E, Farin FM, Srinouanprachanh S, Afsharinejad Z, Mandelson MT, Brentnall TA, Barnett MJ, Goodman GE, Austin MA.

J Gastrointest Cancer. 2010 Sep;41(3):203-8. doi: 10.1007/s12029-010-9130-7.

20.

A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33.

Petersen GM, Amundadottir L, Fuchs CS, Kraft P, Stolzenberg-Solomon RZ, Jacobs KB, Arslan AA, Bueno-de-Mesquita HB, Gallinger S, Gross M, Helzlsouer K, Holly EA, Jacobs EJ, Klein AP, LaCroix A, Li D, Mandelson MT, Olson SH, Risch HA, Zheng W, Albanes D, Bamlet WR, Berg CD, Boutron-Ruault MC, Buring JE, Bracci PM, Canzian F, Clipp S, Cotterchio M, de Andrade M, Duell EJ, Gaziano JM, Giovannucci EL, Goggins M, Hallmans G, Hankinson SE, Hassan M, Howard B, Hunter DJ, Hutchinson A, Jenab M, Kaaks R, Kooperberg C, Krogh V, Kurtz RC, Lynch SM, McWilliams RR, Mendelsohn JB, Michaud DS, Parikh H, Patel AV, Peeters PH, Rajkovic A, Riboli E, Rodriguez L, Seminara D, Shu XO, Thomas G, Tjønneland A, Tobias GS, Trichopoulos D, Van Den Eeden SK, Virtamo J, Wactawski-Wende J, Wang Z, Wolpin BM, Yu H, Yu K, Zeleniuch-Jacquotte A, Fraumeni JF Jr, Hoover RN, Hartge P, Chanock SJ.

Nat Genet. 2010 Mar;42(3):224-8. doi: 10.1038/ng.522. Epub 2010 Jan 24.

21.

Association between the peroxisome proliferator-activated receptor gamma Pro12Ala variant and haplotype and pancreatic cancer in a high-risk cohort of smokers: a pilot study.

Fesinmeyer MD, Stanford JL, Brentnall TA, Mandelson MT, Farin FM, Srinouanprachanh S, Afsharinejad Z, Goodman GE, Barnett MJ, Austin MA.

Pancreas. 2009 Aug;38(6):631-7. doi: 10.1097/MPA.0b013e3181a53ef9.

22.

Colorectal cancer risk in relation to use of acid suppressive medications.

Chubak J, Boudreau DM, Rulyak SJ, Mandelson MT.

Pharmacoepidemiol Drug Saf. 2009 Jul;18(7):540-4. doi: 10.1002/pds.1749.

23.

Cardiovascular medication use and risk for colorectal cancer.

Boudreau DM, Koehler E, Rulyak SJ, Haneuse S, Harrison R, Mandelson MT.

Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3076-80. doi: 10.1158/1055-9965.EPI-08-0095. Epub 2008 Oct 28.

24.

Ulcerative colitis is a disease of accelerated colon aging: evidence from telomere attrition and DNA damage.

Risques RA, Lai LA, Brentnall TA, Li L, Feng Z, Gallaher J, Mandelson MT, Potter JD, Bronner MP, Rabinovitch PS.

Gastroenterology. 2008 Aug;135(2):410-8. doi: 10.1053/j.gastro.2008.04.008. Epub 2008 Apr 15.

25.

Leptin concentrations, leptin receptor polymorphisms, and colorectal adenoma risk.

Chia VM, Newcomb PA, Lampe JW, White E, Mandelson MT, McTiernan A, Potter JD.

Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2697-703.

26.

Outcome of follow-up colon examination among a population-based cohort of colorectal cancer patients.

Rulyak SJ, Lieberman DA, Wagner EH, Mandelson MT.

Clin Gastroenterol Hepatol. 2007 Apr;5(4):470-6; quiz 407. Epub 2007 Jan 31.

PMID:
17270502
27.

Telomere length in the colon declines with age: a relation to colorectal cancer?

O'Sullivan J, Risques RA, Mandelson MT, Chen L, Brentnall TA, Bronner MP, Macmillan MP, Feng Z, Siebert JR, Potter JD, Rabinovitch PS.

Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):573-7.

28.

Use of antidepressant medications in relation to the incidence of breast cancer.

Fulton-Kehoe D, Rossing MA, Rutter C, Mandelson MT, Weiss NS.

Br J Cancer. 2006 Apr 10;94(7):1071-8.

29.

Costs and survival of patients with colorectal cancer in a health maintenance organization and a preferred provider organization.

Kerrigan M, Howlader N, Mandelson MT, Harrison R, Mansley EC, Ramsey SD.

Med Care. 2005 Oct;43(10):1043-8.

PMID:
16166874
30.

Measures for ascertaining use of colorectal cancer screening in behavioral, health services, and epidemiologic research.

Vernon SW, Meissner H, Klabunde C, Rimer BK, Ahnen DJ, Bastani R, Mandelson MT, Nadel MR, Sheinfeld-Gorin S, Zapka J.

Cancer Epidemiol Biomarkers Prev. 2004 Jun;13(6):898-905. No abstract available.

31.

Health plan policies and programs for colorectal cancer screening: a national profile.

Klabunde CN, Riley GF, Mandelson MT, Frame PS, Brown ML.

Am J Manag Care. 2004 Apr;10(4):273-9.

32.

Hormone replacement therapy in relation to survival in women diagnosed with colon cancer.

Mandelson MT, Miglioretti D, Newcomb PA, Harrison R, Potter JD.

Cancer Causes Control. 2003 Dec;14(10):979-84.

PMID:
14750537
33.

Clinical and sociodemographic factors associated with colon surveillance among patients with a history of colorectal cancer.

Rulyak SJ, Mandelson MT, Brentnall TA, Rutter CM, Wagner EH.

Gastrointest Endosc. 2004 Feb;59(2):239-47.

PMID:
14745398
34.

Cancer-attributable costs of diagnosis and care for persons with screen-detected versus symptom-detected colorectal cancer.

Ramsey SD, Mandelson MT, Berry K, Etzioni R, Harrison R.

Gastroenterology. 2003 Dec;125(6):1645-50.

PMID:
14724816
35.

Validity of self-reported mammography: examining recall and covariates among older women in a Health Maintenance Organization.

Caplan LS, Mandelson MT, Anderson LA; Health Maintenance Organization.

Am J Epidemiol. 2003 Feb 1;157(3):267-72.

PMID:
12543627
36.

Predictors of sensitivity of clinical breast examination (CBE).

Oestreicher N, White E, Lehman CD, Mandelson MT, Porter PL, Taplin SH.

Breast Cancer Res Treat. 2002 Nov;76(1):73-81.

PMID:
12408378
37.

Screening mammography: clinical image quality and the risk of interval breast cancer.

Taplin SH, Rutter CM, Finder C, Mandelson MT, Houn F, White E.

AJR Am J Roentgenol. 2002 Apr;178(4):797-803.

PMID:
11906848
38.

Variation in mammographic breast density by race.

El-Bastawissi AY, White E, Mandelson MT, Taplin S.

Ann Epidemiol. 2001 May;11(4):257-63.

PMID:
11306344
39.

Changes in breast density associated with initiation, discontinuation, and continuing use of hormone replacement therapy.

Rutter CM, Mandelson MT, Laya MB, Seger DJ, Taplin S.

JAMA. 2001 Jan 10;285(2):171-6.

PMID:
11176809
40.

Reproductive and hormonal factors associated with mammographic breast density by age (United States).

El-Bastawissi AY, White E, Mandelson MT, Taplin SH.

Cancer Causes Control. 2000 Dec;11(10):955-63.

PMID:
11142530
41.

Performance of screening mammography among women with and without a first-degree relative with breast cancer.

Kerlikowske K, Carney PA, Geller B, Mandelson MT, Taplin SH, Malvin K, Ernster V, Urban N, Cutter G, Rosenberg R, Ballard-Barbash R.

Ann Intern Med. 2000 Dec 5;133(11):855-63.

PMID:
11103055
42.

A record-based evaluation of induced abortion and breast cancer risk (United States).

Newcomb PA, Mandelson MT.

Cancer Causes Control. 2000 Oct;11(9):777-81.

PMID:
11075865
43.

Colorectal cancer screening participation by older women.

Mandelson MT, Curry SJ, Anderson LA, Nadel MR, Lee NC, Rutter CM, LaCroix AZ.

Am J Prev Med. 2000 Oct;19(3):149-54.

PMID:
11020590
44.

Does provider prevention orientation influence female patients' preventive practices?

Greenlund KJ, Keenan NL, Anderson LA, Mandelson MT, Newton KM, LaCroix AZ.

Am J Prev Med. 2000 Aug;19(2):104-10.

PMID:
10913900
45.

Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers.

Mandelson MT, Oestreicher N, Porter PL, White D, Finder CA, Taplin SH, White E.

J Natl Cancer Inst. 2000 Jul 5;92(13):1081-7.

PMID:
10880551
46.

Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers.

Porter PL, El-Bastawissi AY, Mandelson MT, Lin MG, Khalid N, Watney EA, Cousens L, White D, Taplin S, White E.

J Natl Cancer Inst. 1999 Dec 1;91(23):2020-8.

PMID:
10580027
47.
48.

Prostate-specific antigen for prostate cancer screening. Do physician characteristics affect its use?

Edlefsen KL, Mandelson MT, McIntosh MW, Andersen MR, Wagner EH, Urban N.

Am J Prev Med. 1999 Jul;17(1):87-90.

PMID:
10429758
49.

Variation in mammographic breast density by time in menstrual cycle among women aged 40-49 years.

White E, Velentgas P, Mandelson MT, Lehman CD, Elmore JG, Porter P, Yasui Y, Taplin SH.

J Natl Cancer Inst. 1998 Jun 17;90(12):906-10.

PMID:
9637139
50.

Cancer screening in HMOs: program development and evaluation.

Mandelson MT, Thompson RS.

Am J Prev Med. 1998 Apr;14(3 Suppl):26-32.

PMID:
9566934

Supplemental Content

Loading ...
Support Center